Literature DB >> 2286652

Sex differences among non-brain-damaged adults on the Wechsler Adult Intelligence Scales: a review of the literature.

W G Snow1, J Weinstock.   

Abstract

We reviewed studies of the performance of non-brain-damaged men and women on the Wechsler Adult Intelligence Scales (i.e., the Wechsler-Bellevue, Wechsler Adult Intelligence Scale, and Wechsler Adult Intelligence Scale-Revised) to determine if there were sex differences on specific test items, on specific subtests, or on Verbal IQ, Performance IQ, or the Verbal-Performance Discrepancy score. There were sex differences on some items of each of the three measures, but the number of such differences was small. A number of studies suggested differences on subtests of these scales. A meta-analysis indicated that females tended to outperform males by about a third of a standard deviation on the Digit Symbol subtest, while males tended to outperform females to the same extent or greater on the Arithmetic and Information subtests. Finally, in the few studies on IQ or discrepancy-score differences, there was no evidence of any consistent differences between the sexes in the Verbal-Performance Discrepancy, although there was some tendency for males to obtain higher Verbal IQs. This review, therefore, does not suggest that there are any major differences between non-brain-damaged males and females on the Wechsler adult intelligence scales.

Entities:  

Mesh:

Year:  1990        PMID: 2286652     DOI: 10.1080/01688639008401028

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  8 in total

1.  Sex-Related Cognitive Profile in Autism Spectrum Disorders Diagnosed Late in Life: Implications for the Female Autistic Phenotype.

Authors:  Fritz-Georg Lehnhardt; Christine Michaela Falter; Astrid Gawronski; Kathleen Pfeiffer; Ralf Tepest; Jeremy Franklin; Kai Vogeley
Journal:  J Autism Dev Disord       Date:  2016-01

2.  Sex difference in cognitive response to antipsychotic treatment in first episode schizophrenia.

Authors:  Leah H Rubin; Gretchen L Haas; Matcheri S Keshavan; John A Sweeney; Pauline M Maki
Journal:  Neuropsychopharmacology       Date:  2007-03-28       Impact factor: 7.853

3.  Effects of sex, menstrual cycle phase, and endogenous hormones on cognition in schizophrenia.

Authors:  Leah H Rubin; C Sue Carter; Lauren L Drogos; Hossein Pournajafi-Nazarloo; John A Sweeney; Pauline M Maki
Journal:  Schizophr Res       Date:  2015-05-16       Impact factor: 4.939

4.  Frontal Callosal Fiber Integrity Selectively Predicts Coordinated Psychomotor Performance in Chronic Alcoholism.

Authors:  Margaret J Rosenbloom; Stephanie A Sassoon; Rosemary Fama; Edith V Sullivan; Adolf Pfefferbaum
Journal:  Brain Imaging Behav       Date:  2008       Impact factor: 3.978

5.  Demographically-adjusted norms for the WAIS-R Block Design and Arithmetic subtests: Results from the Neuropsychological Norms for the US-Mexico Border Region in Spanish (NP-NUMBRS) project.

Authors:  Travis M Scott; Alejandra Morlett Paredes; Michael J Taylor; Anya Umlauf; Lidia Artiola I Fortuny; Robert K Heaton; Mariana Cherner; María J Marquine; Monica Rivera Mindt
Journal:  Clin Neuropsychol       Date:  2020-01-13       Impact factor: 4.373

6.  Cognitive Impairment in Non-critical, Mild-to-Moderate COVID-19 Survivors.

Authors:  Ashley M Henneghan; Kimberly A Lewis; Eliana Gill; Shelli R Kesler
Journal:  Front Psychol       Date:  2022-02-17

7.  Frontal brain dysfunction in alcoholism with and without antisocial personality disorder.

Authors:  Marlene Oscar-Berman; Mary M Valmas; Kayle S Sawyer; Shalene M Kirkley; David A Gansler; Diane Merritt; Ashley Couture
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

8.  Mercury derived from dental amalgams and neuropsychologic function.

Authors:  Pam Factor-Litvak; Gunnar Hasselgren; Diane Jacobs; Melissa Begg; Jennie Kline; Jamie Geier; Nancy Mervish; Sonia Schoenholtz; Joseph Graziano
Journal:  Environ Health Perspect       Date:  2003-05       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.